Lung cancer is the leading cause of cancer related mortality. Among them, non small cell lung cancer accounts for 85%. Only part of patients could be treated with radical surgery. Mitochondria-targeted system therapy combined with radiofrequency ablation could be an alternative treatment. Small sample clinical cases verified that this therapy could be an efficacy and safe treatment in a short period. The primary aim of this trial is to determine if the efficacy of mitochondria-targeted system therapy combined with radiofrequency ablation is comparable to that of standard surgical interventions for patients with non-small cell lung cancer.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
1,753
Patients will be treated with mitochondria-targeted system therapy and radiofrequency ablation in the primary tumor sites
Patients will be treated with surgery
Shanghai 10th People's Hospital
Shanghai, Shanghai Municipality, China
RECRUITINGDisease-free survival
Time frame: From the date of randomization until the date of first documented progression，assessed up to 60 months
Overall survival
Time frame: From the date of randomization until the date of death from any cause，assessed up to 60 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.